The DOI matches its Crossref record; 113 of the 114 references it cites were found in a registry or an index.
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Open accessAbstract
A consensus panel from the United States and Europe was convened recently to update and revise the 1997 consensus guidelines for the neuropathologic evaluation of Alzheimer's disease (AD) and other diseases of brain that are common in the elderly. The new guidelines recognize the pre‐clinical stage of AD, enhance the assessment of AD to include amyloid accumulation as well as neurofibrillary change and neuritic plaques, establish protocols for the neuropathologic assessment of Lewy body disease, vascular brain injury, hippocampal sclerosis, and TDP‐43 inclusions, and recommend standard approaches for the workup of cases and their clinico‐pathologic correlation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinically, there is a long, prodromal stage in AD prior to the irreversibly progressive decline of cognition (Hyman et al., 2012).”
From Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression (2020) · cites this paper as Hyman et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current criteria use an ABC scoring system that requires the presence of amyloid plaques and tau neurofibrillary tangles to describe the amount of AD neuropathological change ranging from none to low to intermediate to high amounts of change.”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both Aβ and paired helical filament (PHF) tau deposits are required to fulfill neuropathologic criteria for AD [105,106]”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The new NIA criteria use the same combination of NPs and Braak stage as the minimum lesion density necessary for attributing the cause of dementia to AD (39, 40).”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the integration of these pathological assessments following the NIAA guidelines gives a classification of AD neuropathological changes of A3B3C3 [16], that can be interpreted as high, similar to other PSEN1E280A cases.”
From Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia (2022) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the integration of these pathological assessments following the NIAA guidelines gives a classification of AD neuropathological changes of A3B3C3 [16], that can be interpreted as high, similar to other PSEN1E280A cases.”
From Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia (2022) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The staging scheme is widely used in neuropathologic criteria for AD [69, 70].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“The most current set of criteria for the neuropathological assessment of Alzheimer’s disease termed the 2012 National Institute on Aging-Alzheimer’s Association Guidelines are based on the semi-quantitative measure of Thal Aβ amyloid phase, Braak NFT stage and CERAD neuritic plaque score, and they are applicable to patients with or without dementia [69].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“For cases with incomplete clinical history, higher levels of AD neuropathologic change typically are correlated with greater likelihood of cognitive impairment [29].”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“The shortcomings of the NIA-Reagan criteria have been recognized and a revised set of criteria are currently in press (39, 40).”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“these findings were consistent with a high degree of AD neuropathology per the National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria [3–7].”
From Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road (2017) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“By NIA-AA criteria, the findings met criteria for “high level” AD neuropathology [3–7].”
From Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road (2017) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Finally, we noticed that the glycolysis pathway genes were maximally expressed at different points in global AD progression for each region (pathology diagnosis by ABC score)29,30.”
From Single-cell multiregion dissection of Alzheimer’s disease (2024) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“Neuropathologic diagnosis of AD was in accordance with current NIA-AA guidelines (Hyman et al., 2012; Montine et al., 2012).”
From Cholesterol and matrisome pathways dysregulated in astrocytes and microglia (2022) · cites this paper as Hyman et al., 2012
In the citing paper
“Neuropathological examination included Braak and Braak staging for plaques and tangles and diagnosis of neuropathological AD using National Institute on Aging-Reagan criteria [47].”
From Microglia facilitate loss of perineuronal nets in the Alzheimer's disease brain (2020) · cites this paper as [47]
In the citing paper
“Anti-inflammatory DAM and pro-inflammatory DAM module members overlapped (FDR < 10%) with human protein modules (M2, M4, M35, unadjusted p-values < 0.01) that were also positively associated with Braak and CERAD neuropathological grades in human AD (Fig. 9e) [58].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [58]
In the citing paper
“Neuropathology criteria for Alzheimer’s disease provide no cutoff for establishing Alzheimer’s disease diagnosis, but only define low, intermediate, or high levels of Alzheimer’s disease neuropathological change.14”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [14]
In the citing paper
“Neuropathological criteria for the diagnosis of AD were established by the National Institute on Aging–Alzheimer Association (NIA–AA)4 and were updated in 2012 to reflect the current thinking on AD pathological assessment.5,6”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
In the citing paper
“Neuropathological assessment was performed by 2 authors (T.G.B. and T.J.M.) blinded to clinical and imaging results and using NIA–AA diagnostic scoring guidelines.5,40”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
In the citing paper
“Furthermore, although these areas are key in early NFT accumulation in AD, isolated tau in these regions can represent B1-level NFTs, which are associated with not or low levels of ADNC.5”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
In the citing paper
“Analyses from the National Alzheimer Coordinating Center pathological database have indicated that individuals with a B2 score had clinically normal result at a rate of 25.3% (34 of 134), and 41 (37.6%) of 109 people with Aβ at autopsy had a B2 score.5”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
In the citing paper
“Results of this study support the hypothesis that, with a high sensitivity and moderate to high specificity, PET imaging with [18F]flortaucipir is able to identify the underlying presence of NFTs at the B3 level and a high level of ADNC per the NIA–AA criteria, consistent with a neuropathological diagnosis of AD.5”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 4×
“zNFT stage should be determined by the method of Braak [19,20].”
InfluentialStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“From the clinical perspective, the concept of AD has evolved to include patients with milder symptoms [2], including the proposition that there is a preclinical phase of the illness [3].”
Self-citationThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Self-citationDeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citation
Cited by
Sorted by citations
Items 601–700 of 1,032
Lewandowski, C. T., Maldonado Weng, J., & LaDu, M. J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104811 · Cited by 72
Distinct effects of beta‐amyloid and tau on cortical thickness in cognitively healthy older adults
Harrison, T. M., Du, R., Klencklen, G., Baker, S. L., & Jagust, W. J. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12249 · Cited by 69
Amidst an amygdala renaissance in Alzheimer’s disease
Stouffer, K. M., Grande, X., Düzel, E., Johansson, M., Creese, B., Witter, M. P., Miller, M. I., Wisse, L. E. M., & Berron, D. (2023) · Brain · doi:10.1093/brain/awad411 · Cited by 72
Islam, T., Hill, E., Abrahamson, E. E., Servaes, S., Smirnov, D. S., Zeng, X., Sehrawat, A., Chen, Y., Kac, P. R., Kvartsberg, H., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03400-0 · Cited by 76
Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity
Moscoso, A., Heeman, F., Raghavan, S., Costoya‐Sánchez, A., van Essen, M., Mainta, I., Camacho, V., Fonseca, O. D. R., Silva‐Rodríguez, J., Perissinotti, A., et al. (2025) · JAMA · doi:10.1001/jama.2025.7817 · Cited by 74
Self-citationSelective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease
Mattsson, N., Schott, J. M., Hardy, J., Turner, M. R., & Zetterberg, H. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311321 · Cited by 72
Turner, R. C., Lucke-Wold, B. P., Robson, M. J., Lee, J. M., & Bailes, J. E. (2016) · Brain Injury · doi:10.1080/02699052.2016.1193631 · Cited by 73
Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer’s disease
Borin, M., Saraceno, C., Catania, M., Lorenzetto, E., Pontelli, V., Paterlini, A., Fostinelli, S., Avesani, A., Di Fede, G., Zanusso, G., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0567-4 · Cited by 68
Khosravi, M., Peter, J., Wintering, N., Serruya, M. D., Shamchi, S. P., Werner, T. J., Alavi, A. A., & Newberg, A. B. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190220 · Cited by 70
BrainNet Europe’s Code of Conduct for brain banking
Klioueva, N. M., Rademaker, M. C., Dexter, D. T., Al‐Sarraj, S., Seilhean, D., Streichenberger, N., Schmitz, P., Bell, J. E., Ironside, J. W., Arzberger, T., et al. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-014-1353-5 · Cited by 68
Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging
Pontecorvo, M. J., Arora, A., Devine, M., Lu, M., Galante, N., Siderowf, A., Devadanam, C., Joshi, A. D., Heun, S. L., Teske, B. F., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3601-4 · Cited by 68
Swanson, M. E. V., Murray, H. C., Ryan, B., Faull, R. L. M., Dragunow, M., & Curtis, M. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-68086-z · Cited by 65
d’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 71
Locci, A., Orellana, H., Rodríguez, G., Gottliebson, M., McClarty, B. M., Dominguez, S., Keszycki, R. M., & Dong, H. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113192 · Cited by 70
Translational approaches to understanding resilience to Alzheimer’s disease
Neuner, S. M., Telpoukhovskaia, M., Menon, V., O’Connell, K. M. S., Hohman, T. J., & Kaczorowski, C. C. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.02.005 · Cited by 68
de Ruyter, F. J. H., Morrema, T. H. J., den Haan, J., Bank, N. B., Twisk, J. W. R., de Boer, J. F., Scheltens, P., Boon, B. D. C., Thal, D. R., Rozemüller, A. J. M., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02525-1 · Cited by 70
Self-citationGAD65, GAD67, and GABAT Immunostaining in Human Brain and Apparent GAD65 Loss in Alzheimer's Disease
Schwab, C., Yu, S. Y., Wong, W., McGeer, E. G., & McGeer, P. L. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121330 · Cited by 71
Sun, X.-H., Dong, Y.-X., Zhang, H.-Y., Li, H.-Y., Liu, P.-H., & Sui, Y. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.232486 · Cited by 67
Müller cell degeneration and microglial dysfunction in the Alzheimer’s retina
Xu, Q., Boerkoel, P., Hirsch‐Reinshagen, V., Mackenzie, I. R., Hsiung, G. R., Charm, G., To, E., Liu, A., Schwab, K. D., Jiang, K., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01448-y · Cited by 68
Sudduth, T. L., Greenstein, A. W., & Wilcock, D. M. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1220-13.2013 · Cited by 71
Thal, D. R., von Arnim, C. A. F., Griffin, W. S. T., Mrak, R. E., Walker, L., Attems, J., & Arzberger, T. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-014-1360-6 · Cited by 67
Self-citationdos Santos, S. B., Rocha, G. P., Fernandez, L. L., de Pádua, A. C., & Reppold, C. T. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.00371 · Cited by 67
Barupal, D. K., Fan, S., Wancewicz, B., Cajka, T., Sa, M., Showalter, M. R., Baillie, R., Tenenbaum, J. D., Louie, G., Initiative, A. D. N., et al. (2018) · Scientific Data · doi:10.1038/sdata.2018.263 · Cited by 65
The need to unify neuropathological assessments of vascular alterations in the ageing brain
Alafuzoff, I., Gelpi, E., Al-Sarraj, S., Arzberger, T., Attems, J., Bodi, I., Bogdanovic, N., Budka, H., Bugiani, O., Englund, E., et al. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.06.001 · Cited by 65
Self-citationNeuropathology and cognitive performance in self-reported cognitively healthy centenarians
Ganz, A. B., Beker, N., Hulsman, M., Sikkes, S. A. M., NBB, Scheltens, P., Smit, A. B., Rozemüller, A. J. M., Hoozemans, J. J. M., & Holstege, H. H. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0558-5 · Cited by 69
Kapasi, A., Brosch, J. R., Nudelman, K. N. H., Agrawal, S., Foroud, T., & Schneider, J. A. (2020) · Neuropathology · doi:10.1111/neup.12687 · Cited by 66
Self-citationGilvesy, A., Husén, E., Maglóczky, Z., Mihály, O. S., Hortobágyi, T., Kanatani, S., Heinsen, H., Renier, N., Hökfelt, T. G. M., Mulder, J., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02477-6 · Cited by 77
TDP-43 pathology is associated with increased tau burdens and seeding
Tomé, S. O., Tsaka, G., Ronisz, A., Ospitalieri, S., Gawor, K., Gomes, L. A., Otto, M., Arnim, C. A. F. V., Damme, P. V., Bosch, L. V. D., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00653-0 · Cited by 74
Self-citationLi, J. J., Dolios, G., Wang, R., & Liao, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090770 · Cited by 65
Mandler, M., Walker, L., Santic, R., Hanson, P. S., Upadhaya, A. R., Colloby, S. J., Morris, C. M., Thal, D. R., Thomas, A. J., Schneeberger, A., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1296-9 · Cited by 65
Self-citationMoreno, F., Rabinovici, G. D., Karydas, A., Miller, Z., Hsu, S. C., Legati, A., Fong, J. C., Schonhaut, D. R., Esselmann, H., Watson, C., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0190-6 · Cited by 69
Quantitative protein profiling of hippocampus during human aging
Xu, B., Gao, Y., Zhan, S., Xiong, F., Qiu, W., Qian, X., Wang, T., Wang, N., Zhang, D., Yang, Q., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.11.029 · Cited by 67
Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration
Seo, S. W., Thibodeau, M., Perry, D. C., Hua, A. Y., Sidhu, M., Sible, I. J., Vargas, J. N. S., Gaus, S. E., Rabinovici, G. D., Rankin, K. D., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005163 · Cited by 67
Self-citationVariation in TMEM106B in chronic traumatic encephalopathy
Cherry, J. D., Mez, J., Crary, J. F., Tripodis, Y., Alvarez, V. E., Mahar, I., Huber, B. R., Alosco, M. L., Nicks, R., Abdolmohammadi, B., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0619-9 · Cited by 67
Cognitive Resilience to Alzheimer’s Disease Pathology in the Human Brain
Bowles, E. J. A., Crane, P. K., Walker, R. L., Chubak, J., LaCroix, A. Z., Anderson, M. L., Rosenberg, D. E., Keene, C. D., & Larson, E. B. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180942 · Cited by 70
Protection of MCC950 against Alzheimer's disease via inhibiting neuronal pyroptosis in SAMP8 mice
Li, J., Zhuang, L., Luo, X., Liang, J., Sun, E., & He, Y. (2020) · Experimental Brain Research · doi:10.1007/s00221-020-05916-6 · Cited by 68
Martini, A. C., Helman, A. M., McCarty, K. L., Lott, I. T., Doran, E., Schmitt, F. A., & Head, E. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12113 · Cited by 66
Progression in Behavioral Variant Frontotemporal Dementia: A Longitudinal Study
Devenney, E., Bartley, L., Hoon, C., O’Callaghan, C., Kumfor, F., Hornberger, M., Kwok, J. B., Halliday, G. M., Kiernan, M. C., Piguet, O., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.2061 · Cited by 61
Ota, K., Oishi, N., Ito, K., & Fukuyama, H. (2015) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2015.08.020 · Cited by 68
Cognitive impairment in progressive supranuclear palsy is associated with tau burden
Koga, S., Parks, A. C., Kasanuki, K., Sánchez-Contreras, M., Baker, M., Josephs, K. A., Ahlskog, J. E., Uitti, R. J., Graff‐Radford, N. R., van Gerpen, J. A., et al. (2017) · Movement Disorders · doi:10.1002/mds.27198 · Cited by 67
Self-citationTredici, K. D., & Braak, H. (2019) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2019.11.008 · Cited by 68
Cognitive Impairment in Older Adults and Therapeutic Strategies
Montine, T. J., Bukhari, S. A., & White, L. R. (2020) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000031 · Cited by 67
Self-citationCalafate, S., Özturan, G., Thrupp, N., Vanderlinden, J., Marinha, L. S., Morais‐Ribeiro, R., Ruggiero, A., Bozic, I., Rusterholz, T., Lorente-Echeverría, B., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01325-4 · Cited by 67
Self-citationHyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis
Murray, P. S., Kirkwood, C. M., Gray, M. C., Fish, K. N., Ikonomović, M. D., Hamilton, R. L., Kofler, J., Klunk, W. E., López, O. L., & Sweet, R. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131166 · Cited by 67
Von Economo neurons of the anterior cingulate across the lifespan and in Alzheimer's disease
Gefen, T. D., Papastefan, S. T., Rezvanian, A., Bigio, E. H., Weıntraub, S., Rogalski, E. J., Mesulam, M. M., & Geula, C. (2017) · Cortex · doi:10.1016/j.cortex.2017.10.015 · Cited by 67
Self-citationEvolution of neuronal and glial tau isoforms in chronic traumatic encephalopathy
Cherry, J. D., Kim, S. H., Stein, T. D., Pothast, M. J., Nicks, R., Meng, G., Huber, B. R., Mez, J., Alosco, M. L., Tripodis, Y., et al. (2020) · Brain Pathology · doi:10.1111/bpa.12867 · Cited by 68
Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases
Mormino, E. C., Toueg, T. N., Azevedo, E. C., Castillo, J. B., Guo, W., Nadiadwala, A., Corso, N. K., Hall, J. N., Fan, A. P., Trelle, A. N., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04923-7 · Cited by 67
Synaptophysin and Synaptojanin-1 in Down Syndrome are Differentially Affected by Alzheimer's Disease
Martin, S. B., Dowling, A. L. S., Lianekhammy, J., Lott, I. T., Doran, E., Murphy, M. P., Beckett, T. L., Schmitt, F. A., & Head, E. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140795 · Cited by 64
Desmarais, P., Gao, A. F., Lanctôt, K. L., Rogaeva, E. A., Ramirez, J., Herrmann, N., Stuss, D. T., Black, S. E., Keith, J. L., & Masellis, M. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00869-6 · Cited by 63
Accumulation of Ambient Black Carbon Particles Within Key Memory-Related Brain Regions
Vanbrabant, K., Dam, D. V., Bongaerts, E., Vermeiren, Y., Bové, H., Hellings, N., Ameloot, M. M., Plusquin, M., Deyn, P. P. D., & Nawrot, T. S. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.5678 · Cited by 64
Alkhazaali-Ali, Z., Negah, S. S., Boroumand, A. R., & Tavakol‐Afshari, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116899 · Cited by 69
Chaalal, A., Poirier, R., Blum, D. L., Gillet, B., Leblanc-Veyrac, P., Basquin, M., Buée, L., Laroche, S., & Enderlin, V. (2014) · Hippocampus · doi:10.1002/hipo.22319 · Cited by 67
Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition
Schultz, S. A., Boots, E. A., Almeida, R. P., Oh, J. M., Einerson, J. A., Korcarz, C. E., Edwards, D. F., Koscik, R. L., Dowling, N. M., Gallagher, C. L., et al. (2015) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617715000843 · Cited by 65
Oh, B., Han, D., Han, K., Liu, X., Ukken, J., Chang, C., Dounis, K., & Yoo, J. W. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0729-z · Cited by 66
Microglial motility in Alzheimer’s disease and after Aβ42 immunotherapy: a human post-mortem study
Franco-Bocanegra, D. K., George, B., Lau, L. C., Holmes, C., Nicoll, J. A. R., & Boche, D. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0828-x · Cited by 64
Seo, S. W., Ayakta, N., Grinberg, L. T., Villeneuve, S., Lehmann, M., Reed, B., DeCarli, C., Miller, B. L., Rosen, H. J., Boxer, A. L., et al. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.11.008 · Cited by 63
King, A., Bódi, I., & Troakes, C. (2020) · Brain Sciences · doi:10.3390/brainsci10080479 · Cited by 69
Panitch, R., Hu, J., Chung, J., Zhu, C., Meng, G., Xia, W., Bennett, D. A., Lunetta, K. L., Ikezu, T., Au, R., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01266-z · Cited by 59
Ferroptosis of Microglia in Aging Human White Matter Injury
Adeniyi, P. A., Gong, X., MacGregor, E., Degener-O’Brien, K., McClendon, E., Garcia, M., Romero, O., Russell, J., Srivastava, T., Miller, J. A., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26770 · Cited by 62
Geigenmüller, J. N., Tari, A. R., Wisløff, U., & Walker, T. L. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14179 · Cited by 66
Graham, S. F., Nasaruddin, M. L., Carey, M. P., Hölscher, C., McGuinness, B., Kehoe, P. G., Love, S., Passmore, P., Elliott, C. T., Meharg, A. A., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140684 · Cited by 63
PET imaging of tau protein targets: a methodology perspective
Lois, C., González, I., Johnson, K. A., & Price, J. C. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-018-9847-7 · Cited by 64
Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain
Horie, K., Barthélemy, N. R., Mallipeddi, N., Li, Y., Franklin, E. E., Perrin, R. J., Bateman, R. J., & Sato, C. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01019-z · Cited by 62
A Practical Guide to the Automated Analysis of Vascular Growth, Maturation and Injury in the Brain
Rust, R., Kirabali, T., Grönnert, L., Doğançay, B., Limasale, Y. D. P., Meinhardt, A., Werner, C., Laviña, B., Kulic, L., Nitsch, R. M., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00244 · Cited by 60
Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis
Walton, C. C., Begelman, D. V., Nguyen, W., & Andersen, J. K. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00129 · Cited by 62
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
Ossenkoppele, R., & Hansson, O. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12356 · Cited by 62
C9 ORF 72 expansion in a family with bipolar disorder
Meisler, M. H., Grant, A. E., Jones, J. M., Lenk, G. M., He, F., Todd, P. K., Kamali, M., Albin, R. L., Lieberman, A. P., Langenecker, S. A., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12063 · Cited by 62
Subthreshold amyloid and its biological and clinical meaning
Bischof, G. N., & Jacobs, H. I. L. (2019) · Neurology · doi:10.1212/wnl.0000000000007747 · Cited by 61
Measuring brain synaptic vesicle protein 2A with positron emission tomography and [ 18 F]UCB‐H
Bahri, M. A., Plenevaux, A., Aerts, J., Bastin, C., Becker, G., Mercier, J., Valade, A., Buchanan, T., Mestdagh, N., Ledoux, D., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.004 · Cited by 61
Association of anxiety with subcortical amyloidosis in cognitively normal older adults
Hanseeuw, B. J., Jonas, V., Jackson, J., Betensky, R. A., Rentz, D. M., Johnson, K. A., Sperling, R. A., & Donovan, N. J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0214-2 · Cited by 61
Comparison of New Tau PET-Tracer Candidates With [ 18 F]T808 and [ 18 F]T807
Declercq, L., Celen, S., Lecina, J., Ahamed, M., Tousseyn, T., Moechars, D., Alcázar, J., Ariza, M., Fierens, K., Bottelbergs, A., et al. (2016) · Molecular Imaging · doi:10.1177/1536012115624920 · Cited by 63
Takeuchi, R., Tada, M., Shiga, A., Toyoshima, Y., Konno, T., Sato, T., Nozaki, H., Kato, T., Horie, M., Shimizu, H., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0335-2 · Cited by 66
Stathas, S., Alvarez, V. E., Xia, W., Nicks, R., Meng, G., Daley, S. A., Pothast, M. J., Shah, A., Kelley, H. J., Esnault, C. D., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12502 · Cited by 62
Chen, P., Han, X., Shaw, T. I., Fu, Y., Sun, H., Niu, M., Wang, Z., Jiao, Y., Teubner, B. J. W., Eddins, D. M., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00290-0 · Cited by 60
Self-citationCryo-EM structure of Alzheimer’s disease tau filaments with PET ligand MK-6240
Kunach, P., Vaquer‐Alicea, J., Smith, M. S., Monistrol, J., Hopewell, R., Moquin, L., Therriault, J., Tissot, C., Rahmouni, N., Massarweh, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52265-x · Cited by 64
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research
Iaccarino, L., Burnham, S. C., Tunali, I., Wang, J., Navitsky, M. A., Arora, A., & Pontecorvo, M. J. (2025) · NeuroImage Clinical · doi:10.1016/j.nicl.2025.103765 · Cited by 68
Carrillo, M. C., Dean, R. A., Nicolas, F., Miller, D. S., Berman, R., Khachaturian, Z. S., Bain, L. J., Schindler, R. J., & Knopman, D. S. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.1762 · Cited by 62
Self-citationAmyloid imaging, Risk Disclosure and Alzheimer’s Disease: Ethical and Practical Issues
Roberts, J. S., Dunn, L. B., & Rabinovici, G. D. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.25 · Cited by 64
Protective properties of lysozyme on β-amyloid pathology: implications for Alzheimer disease
Helmfors, L., Boman, A., Civitelli, L., Nath, S., Sandin, L., Janefjord, C., McCann, H., Zetterberg, H., Blennow, K., Halliday, G. M., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.024 · Cited by 62
Vandal, M., White, P. J., Tournissac, M., Tremblay, C., St‐Amour, I., Drouin‐Ouellet, J., Bousquet, M., Traversy, M.-T., Planel, E., Marette, A., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.024 · Cited by 64
Duration and Pathologic Correlates of Lewy Body Disease
Graff‐Radford, J., Aakre, J. A., Savica, R., Boeve, B. F., Kremers, W. K., Ferman, T. J., Jones, D. T., Kantarci, K., Knopman, D. S., Dickson, D. W., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.4926 · Cited by 61
Self-citationApplying fluid biomarkers to Alzheimer's disease
Zetterberg, H. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00007.2017 · Cited by 63
The Neuroanatomy of the Reticular Nucleus Locus Coeruleus in Alzheimer’s Disease
Giorgi, F. S., Ryskalin, L., Ruffoli, R., Biagioni, F., Limanaqi, F., Ferrucci, M., Busceti, C. L., Bonuccelli, U., & Fornai, F. (2017) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2017.00080 · Cited by 63
Neuroprotective Effects of Soy Isoflavones on Scopolamine-Induced Amnesia in Mice
Lü, C., Wang, Y., Wang, D., Zhang, L., Lv, J., Jiang, N., Fan, B., Liu, X., & Wang, F. (2018) · Nutrients · doi:10.3390/nu10070853 · Cited by 61
Martínez, D. B., Soldevilla, M. A. G., Santiago, A. P., & Martínez, J. T. (2019) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2019.03.012 · Cited by 65
Ferrer, I., Andrés‐Benito, P., Ausín, K., Pamplona, R., del Río, J. A., Fernández‐Irigoyen, J., & Santamaría, E. (2021) · Brain Pathology · doi:10.1111/bpa.12996 · Cited by 61
Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer’s disease
Contador, J., Pérez‐Millan, A., Tort‐Merino, A., Balasa, M., Falgàs, N., Olives, J., Castellví, M., Borrego‐Écija, S., Bosch, B., Fernández‐Villullas, G., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102804 · Cited by 64
T cell-mediated microglial activation triggers myelin pathology in a mouse model of amyloidosis
Kedia, S., Ji, H., Feng, R., Androvic, P., Spieth, L., Liu, L., Franz, J., Zdiarstek, H., Anderson, K. P., Kaboglu, C., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01682-8 · Cited by 63
Analysis of RNA from Alzheimer’s Disease Post-mortem Brain Tissues
Clement, C., Hill, J. M., Dua, P., Culicchia, F., & Lukiw, W. J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9105-6 · Cited by 54
TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT
Ling, H., Kara, E., Bandopadhyay, R., Hardy, J., Holton, J. L., Xiromerisiou, G., Lees, A. J., Houlden, H., & Révész, T. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.011 · Cited by 60
Serrano‐Pozo, A., Aldridge, G. M., & Zhang, Q. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170184 · Cited by 59
Edlow, B. L., Keene, C. D., Perl, D. P., Iacono, D., Folkerth, R. D., Stewart, W. B., Jr., Donald, C. L. M., Augustinack, J. C., Diaz-Arrastia, R. R., Estrada, C., et al. (2018) · Journal of Neurotrauma · doi:10.1089/neu.2017.5457 · Cited by 59
Thomas, A. J., Mahin-Babaei, F., Saidi, M., Lett, D. J., Taylor, J., Walker, L., & Attems, J. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0356-0 · Cited by 64
Ghirelli, A., Tosakulwong, N., Weigand, S. D., Clark, H. M., Ali, F., Botha, H., Duffy, J. R., Utianski, R. L., Buciuc, M., Murray, M. E., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25893 · Cited by 59
Self-citationVergallo, A., Bun, R., Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Cavedo, E., Lamari, F., Habert, M., Dubois, B., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.06.3053 · Cited by 59
Guennewig, B., Lim, J., Marshall, L. L., McCorkindale, A. N., Paasila, P. J., Patrick, E., Kril, J. J., Halliday, G. M., Cooper, A. A., & Sutherland, G. T. (2021) · Scientific Reports · doi:10.1038/s41598-021-83872-z · Cited by 59
Orellana, A., García‐González, P., Valero, S., Montrreal, L., de Rojas, I., Hernández, I., Rosende‐Roca, M., Vargas, L., Tartari, J. P., Antonio, E. E., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136891 · Cited by 57
Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease
Ali, M., Archer, D. B., Gorijala, P., Western, D., Timsina, J., Fernández, M. V., Wang, T.-C., Satizabal, C. L., Yang, Q., Beiser, A. S., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01563-4 · Cited by 54
Cappelletti, C., Henriksen, S. P., Geut, H., Rozemüller, A. J. M., van de Berg, W. D. J., Pihlstrøm, L., & Toft, M. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02597-7 · Cited by 58
Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease
Devanarayan, V., Doherty, T., Charil, A., Sachdev, P., Ye, Y., Murali, L. K., Llano, D. A., Zhou, J., Reyderman, L., Hampel, H. J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14073 · Cited by 61
Metadata
- Authors
- Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., Nelson, P. T., Schneider, J. A., Thal, D. R., Thies, B., Trojanowski, J. Q., Vinters, H. V., & Montine, T. J.
- Affiliations
- Harvard University (US)
- National Institutes of Health (US)
- Banner Sun Health Research Institute (US)
- Northwestern University (US)
- Washington University in St. Louis (US)
- Alzheimer's Association Chicago IL USA
- Mayo Clinic (US)
- Service de Neuropathologie Raymond Escourolle Hôpital de la Salpêtriére Paris France
- University of California San Diego (US)
- SUNY Downstate Health Sciences University (US)
- University of Kentucky (US)
- Rush University Medical Center (US)
- Universität Ulm (DE)
- Alzheimer's Association (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Washington (US)
- Corresponding author
- Montine, Thomas J.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2012-01
- Volume
- 8
- Issue
- 1
- Pages
- 1-13
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3266529
- OpenAlex
- W2143461767
- Cited by
- 3,092
- References
- 114
- Citations by year
- 2026: 214 · 2025: 285 · 2024: 286 · 2023: 233 · 2022: 260 · 2021: 327 · 2020: 247 · 2019: 228 · 2018: 206 · 2017: 190 · 2016: 170 · 2015: 161 · 2014: 118 · 2013: 115 · 2012: 46
- FWCI
- 98.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Alzheimer's Association
- Arizona Department of Health Services (211002)
- Arizona Alzheimer’s Consortium
- Deutsche Forschungsgemeinschaft (DFG TH‐624‐4‐1)
- Alzheimer Forschung Initiative (AFI #10810)
- Nancy and Buster Alvord Endowment
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Brain, Humans, Societies, Medical, United States, Consensus Development Conferences, NIH as Topic, Practice Guidelines as Topic, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
